Julia V. T.
- Country
- Germany
- Department
- Clinic of Hematology, Oncology and Palliative Medicine
Research Overview
- Phase II Open‑Label Multicenter Study of Subcutaneous Epcoritamab in Relapsed/Refractory Marginal Zone Lymphoma (EPOS‑1)
- Phase 1/2 Open‑Label Study of RAS(ON) Inhibitor RMC-6291 with ivonescimab ± combination therapy in patients with advanced RAS‑mutated solid tumors
- Phase 3 Randomized Study of Pirtobrutinib, Venetoclax, and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Data & Insights
Has run more than one trial at 42 of 168 partner sites.
Specializations
Lymphoid Malignancies
This investigator specializes in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), with particular focus on developing innovative therapeutic approaches for relapsed and refractory cases.
- Novel Treatment Combinations
- Targeted Therapies
- Fixed Duration Treatments
The research extends to evaluating breakthrough medications and their pharmacological properties in adult patients.
Indolent Lymphomas
Primary research interest centers on follicular lymphoma and marginal zone lymphoma, investigating both frontline treatments and strategies for relapsed/refractory disease.
- Immunotherapy Combinations
- Chemotherapy Optimization
- Response Assessment
Work includes evaluation of novel therapeutic combinations and their comparative efficacy against standard treatments.
Treatment Innovation
The investigator focuses on developing combination therapy approaches incorporating both established and emerging treatments for lymphoid malignancies.
- Safety Assessments
- Long-term Outcomes
- Treatment Duration Optimization
Research encompasses evaluation of treatment tolerability and progression-free survival outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.